Navigation Links
Non-Hormonal Therapies Aid Breast Cancer Patients
Date:12/9/2008

This applies to women with metastatic or recurrent inoperable disease, report says

TUESDAY, Dec. 9 (HealthDay News) -- Over the last 35 years, non-hormonal treatments have improved overall survival of patients with advanced breast cancer.

So say Greek researchers who conducted a review of 128 clinical trials that included more than 26,000 women with the disease.

The review showed that use of anthracycline regimens led to a 22 percent relative risk reduction in overall death, compared with older single-agent chemotherapy. Single drug taxane treatment led to a relative risk reduction of 33 percent, while a combination of a taxane with capecitabine or gemcitabine led to a 51 percent relative risk reduction over single-agent chemotherapy.

Most of the regimens appeared to be effective whether or not women had received a prior treatment.

"Our meta-analysis quantifies the progress achieved in the treatment of advanced breast cancer with nonhormonal systemic treatment in the last 35 years. Several regimens have shown effectiveness, and for some of them, the treatment effects are practically indistinguishable in magnitude," the review authors wrote. "Given that subsequent lines of treatment can confer similar relative benefits as the first-line setting, one can exploit the survival benefits conferred by several effective regimens used in sequential fashion."

The study was published Dec. 9 in the Journal of the National Cancer Institute.

This review is important because there has been no consensus regarding the best dosage, timing, sequence or combination of therapies for treatment of metastatic breast cancer, due to the fact that standard comparators haven't been available, Dr. Philippe Bedard and Dr. Martine Piccart-Gebhart, of the Jules Bordet Institute in Brussels, Belgium, wrote in an accompanying editorial.

The finding that many of the regimens have similar relative effectiveness in both untreated and previously treated patients means that other considerations, such as toxicity, will continue to help determine the choice of regimen for individual patients, the researchers said.

"Although this network meta-analysis is unlikely to alter routine clinical practice, it provides a solid evidence-based foundation to support the observation that the survival of women diagnosed with advanced breast cancer has improved because of more active systemic chemotherapy and targeted therapy," Bedard and Piccart-Gebhart wrote. "This should provide hope to patients, investigators, industrial sponsors, and regulatory agencies alike that well-designed clinical trials with novel systemic therapies can further alter the natural history of this devastating disease."

More information

Breastcancer.org has more about recurrent and metastatic breast cancer.



-- Robert Preidt



SOURCE: Journal of the National Cancer Institute, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Bogus Stem Cell Therapies Sold on Internet
2. Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017
3. Non-white med students reject therapies associated with their culture
4. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
5. Stem cell therapies for heart disease -- 1 step closer
6. Texcel Introduces Innovative Programmable, Implantable Stimulation System for R&D of Specialty Stimulation Therapies
7. Study shows steroid therapies following transplant can be eliminated
8. Study Evaluates Laser Therapies for Hair Removal
9. New Journal to Explore Neurodegenerative, Neuroprotective and Euroregenerative Therapies!
10. New way to control protein activity could lead to cancer therapies
11. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health ... Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage ... is an exciting addition to our provider network, and the addition will benefit ...
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, a northern ... throughout the region, is launching a charity drive to raise awareness of heart disease ... deadliest killer in America, and is responsible for 1 in every 4 deaths at ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , the only ... real-time, today announced a strategic partnership with TechLab Security, a leading ... partners, TechLab Security has become a strategic partner and a value added reseller ...
(Date:1/17/2017)... ... January 17, 2017 , ... Many people make New Year’s resolutions or renew their commitment ... is making it easier for people who want to kick off 2017 with better smiles. ... patients. , These special offers include: , , A new ...
(Date:1/16/2017)... ... January 17, 2017 , ... Recently, patients and staff from A ... other volunteers and organizations in support of the annual Binder Park Zoo Halloween celebration ... up in colorful costumes of all designs coming out to enjoy games, face painting, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017   Anesthesia Business Consultants ... practice management for the anesthesia and pain management ... remains a "clinical conundrum" (as described recently in ... practitioners to think carefully before recommending medical marijuana ... by the National Academies of Sciences, Engineering and ...
(Date:1/17/2017)... N.J. , Jan. 17, 2017 Interpace Diagnostics ... provides clinically useful molecular diagnostic tests and pathology services ... has received a letter dated January 13, 2017 from ... has regained compliance with the requirement of the NASDAQ ... of $1.00 per share. The letter noted ...
(Date:1/17/2017)... 2017  Maureen L. Mulvihill, President and CEO ... 6 senior sales leaders to support the nationwide ... leaders were formerly part of the top producers ... recognized for their performance, they have a proven ... relationships with key customer constituencies. "I have ...
Breaking Medicine Technology: